Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 6Carcinoma, Ovarian Epithelial 4Urinary Bladder Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Lung Neoplasms 1Dysgerminoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 182Radiotherapy 81Paclitaxel 80Brachytherapy 74Carboplatin 72pembrolizumab 63Bevacizumab 40Surveys and Questionnaires 29Colposcopy 29Radiation 28Gemcitabine 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 27Topotecan 26Magnetic Resonance Spectroscopy 24Blood Specimen Collection 23human papillomavirus vaccine, L1 type 16, 18 22Nivolumab 22Drug Therapy 22Papillomavirus Vaccines 20atezolizumab 19Platinum 19Radiotherapy, Intensity-Modulated 18Biopsy 18Docetaxel 17Taxes 16Cyclophosphamide 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Lapatinib × Gynecologic × Clear all
NCT00430781 2015-05-08

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

GlaxoSmithKline

Phase 2 Completed
228 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡